TrialTargeted oncology2023

Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial.

Robert J Motzer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.